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Background
Folate Binding Protein (FBP) is overexpressed in breast,
endometrial, and ovarian cancers. E39 (FBP191-199,
EIWTHSYKV) is an HLA-A2 restricted FBP peptide vac-
cine already shown to generate significant in vivo immuno-
logic response (IR) in a Phase I/IIa trial in endometrial and
ovarian cancer. We are investigating a novel vaccination
series using E39 and E39’ (EIWTFSTKV), an attenuated
version of E39, in a Phase Ib, randomized, single-center
trial (NCT020196524) evaluating IR and monitoring long-
term immunity. We present the initial IR analysis to the
primary vaccination series (PVS).
Methods
HLA-A2+ breast or ovarian cancer patients were enrolled
after completion of standard of care therapy and rando-
mized into three arms: EE-6 inoculations of E39; EE’-3
inoculations of E39 then 3 of E39’; or E’E-3 inoculations
of E39’ then 3 of E39. PVS includes 6 inoculations total,
one every 3-4 weeks containing 250mcg GM-CSF +
500mcg peptide in the first 5 patients per arm and
1000mcg of peptide in second 5 patients. To assess the in
vivo IR, local reaction(LR) was measured 48hours after
each inoculation (R1-6), and delayed type hypersensitivity
(DTH) was measured pre-vaccine(R0), 1 and 6-months
after the PVS (RC1, RC6). Ex vivo IR was measured via
dextramer assay for E39-specific CD8+ T-cells at R0,
RC1, and RC6. Statistical analyses included descriptive
statistics, t-test, Chi-squared, Fisher’s exact test and
ANOVA as appropriate.
Results
Thirty-two patients were enrolled (EE n=10, EE’ n=11,
E’E n=11), with no clinicopathologic differences between
groups, or significant toxicities appreciated. In vivo LR
showed a significant difference within EE and EE’ arms.
LR peaked in EE at R4, while EE’ continued to increase
in size throughout the PVS(EE p=0.04, EE’ p=0.02, E’E
p=0.74). An increase in in vivo DTH was observed
within arm EE’ from R0-RC1-RC6 (EE p=0.72, EE’ p <
0.05, E’E p=0.41). Ex vivo analysis of IR revealed no sig-
nificant difference between groups (p=0.39), nor within
groups (EE p=0.82, EE’ p=0.58, E’E p=0.49).
Conclusion
In this Phase Ib trial comparing three vaccination strate-
gies in ovarian and breast cancer patients, preliminary
analysis revealed E39, given sequentially with or without
E39’, is immunogenic. The in vivo response is enhanced
with the use of the attenuated E39’ after E39. This was
observed in the EE’ arm, this vaccination sequence pro-
ducing the most prominent LR and DTH responses.
Continued analysis of immunologic responses as more
data is obtained will further elucidate the optimal vacci-
nation series for the prevention of recurrence in breast
and ovarian cancer.
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